Patient, the victim of autoimmune diseases
What Makes AbolerIS Unique
All these issues impact the lives of patients suffering from autoimmune diseases, of which Rheumatoid Arthritis (RA) is one of the most common.
Our Innovative Solution
Furthermore, AbolerIS` monoclonal antibody also spares T-regulatory cells (`Tregs`). By eliminating the harmful CD45RC-positive T cells, Tregs can unleash their full potential and suppress ongoing and future autoimmune activity in the adaptive immune system. Hence, therapy with ABO21009 would enable a long-lasting and durable remission in RA, obviating the need for frequent administration of multiple drugs with unwarranted side effects.
Solid scientific results are the foundation of AbolerIS Pharma, and will remain the driver of the company’s development activities.